Patent · US Active

Selective androgen receptor degrader (SARD) ligands and methods of use thereof

US10093613B2 · kind B2 · utility

8Cited by

14References

10Claims

0Family size

Assignees

GTX Corp · US
University of Tennessee Research Foundation · US

Inventors

Ramesh Narayanan · Cordova, US
Duane D. Miller · Germantown, US
Thamarai Ponnusamy · Memphis, US
Dong-Jin Hwang · Arlington, US
Charles B. Duke · Memphis, US
Christopher C. Coss · Upper Arlington, US
Amanda Jones · Gaylord, US
James T. Dalton · Columbus, US

Key dates

Filing date	Dec 4, 2017
Grant date	Oct 9, 2018
Priority date	—
Expiry date	Dec 4, 2037

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This invention provides novel 3-amino propanamide selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.